Precision Immuno-Oncology Market to grow with a CAGR of 9.85% through 2030
Advancements in Immunotherapy and Increasing Biomarker Discovery are expected to drive the demand of Global Precision Immuno-Oncology Market in the forecast period 2026-2030
According
to TechSci Research report, “Precision Immuno-Oncology Market - Global Industry Size, Share, Trends, Competition Forecast & Opportunities, 2030”, Global Precision
Immuno-Oncology Market has valued at USD 62.24 Billion in 2024 and is anticipated
to witness an impressive growth in the forecast period with a CAGR of 9.85%
through 2030.
Collaborations and partnerships among leading companies are key drivers in advancing precision immuno-oncology, as they bring together diverse expertise to enhance market positioning and drive innovation. A critical factor fueling the demand for precision immuno-oncology is genomic and molecular profiling. Techniques like next-generation sequencing (NGS) are instrumental in identifying genetic mutations and alterations within tumors, providing essential data to determine whether a cancer is susceptible to precision immuno-oncology treatments. This profiling also allows for predictions regarding a patient’s potential response to immunotherapy. For instance, high tumor mutational burden (TMB) or the presence of specific genetic markers may indicate a stronger response to immune checkpoint inhibitors.
Genomic and molecular profiling further facilitates the identification of potential therapeutic synergies. By analyzing the genetic makeup of a tumor, clinicians can optimize treatment combinations—such as pairing immunotherapy with targeted therapies or radiation—tailored to individual patients. Profiling also enables patient selection for clinical trials exploring precision immuno-oncology treatments, thereby accelerating drug development and broadening treatment options. Additionally, molecular profiling techniques, including liquid biopsies, allow for continuous monitoring of treatment responses. This enables clinicians to adjust treatment plans promptly in response to signs of resistance or disease progression.
One of the primary goals of precision immuno-oncology is to minimize overtreatment by avoiding therapies that are unlikely to be effective, thereby reducing unnecessary side effects and enhancing patients' quality of life. Throughout treatment, ongoing monitoring ensures that treatment strategies remain aligned with the patient’s evolving condition. If resistance or disease progression is detected, adjustments can be made based on continuous genomic and immune profiling.
However, a key challenge in the global precision immuno-oncology market is the limited patient eligibility for these therapies. This limitation stems from several factors that restrict the number of patients who can benefit from precision-based approaches. Precision immuno-oncology heavily depends on specific biomarkers, such as PD-L1 expression, tumor mutational burden (TMB), or particular genetic mutations. Patients who lack these biomarkers may not qualify for targeted or immunotherapeutic treatments. Moreover, tumor heterogeneity—where different areas of the same tumor exhibit distinct genetic profiles—can complicate the accuracy of biomarker assessments. In some instances, a biopsy from a single region may not fully reflect the genetic makeup of the entire tumor, potentially resulting in inaccurate eligibility determinations. Additionally, the relative rarity of some biomarkers means that only a small subset of patients with specific cancer types will have access to targeted therapies or clinical trials, further limiting the pool of eligible patients.
Browse
over XX market data Figures and spread through XX Pages and an in-depth TOC on
"Global Precision Immuno-Oncology Market”
Global Precision Immuno-Oncology Market is
segmented based on Cancer Type, Treatment Type, Biomarker, End User, by
regional distribution and Company.
Based on Biomarker,
Global Precision Immuno-Oncology Market is segmented into PD-L1, BRCA, KRAS,
EGFR, and others. PD-L1 inhibitors, often used in the form of immune checkpoint inhibitors, have demonstrated clinical success in the treatment of various cancer types. These inhibitors can block the interaction between PD-L1 on tumor cells and PD-1 on immune cells, thereby enhancing the immune system's ability to attack cancer cells. PD-L1 expression levels are commonly used as biomarkers to guide the selection of patients who are more likely to respond to PD-L1 inhibitors. Biomarker testing helps identify individuals who may benefit from these therapies, making treatment more personalized. Researchers and clinicians often explore combination therapies that include PD-L1 inhibitors with other precision immuno-oncology treatments, such as targeted therapies or immunotherapies like CAR-T cell therapy. These combinations aim to enhance treatment responses.
Based on region Asia Pacific is poised to witness fastest market growth in the Global Precision Immuno-Oncology Market. The cancer burden in the APAC region is increasing at an alarming rate, driven by factors such as aging populations, lifestyle changes, and increasing exposure to environmental risk factors. According to recent reports, cancer is the leading cause of death in several APAC countries, and the number of new cancer cases is projected to continue rising. This growing prevalence of cancer is driving demand for advanced, targeted, and personalized treatments, particularly in precision immuno-oncology, as traditional therapies often fail to deliver effective results across diverse patient populations. Many APAC countries are significantly investing in improving healthcare infrastructure, both in terms of technology and treatment facilities. For instance, countries like China, India, Japan, and South Korea are prioritizing healthcare reform, increasing government spending, and enhancing their biotechnology and pharmaceutical industries. These advancements are creating a conducive environment for the adoption of precision medicine, including immuno-oncology therapies. The increase in government and private-sector investment in the healthcare sector is fueling research and development in cancer diagnostics and treatment, further accelerating the growth of precision immuno-oncology in the region.
A key enabler for the adoption of precision immuno-oncology in the APAC region is the growing availability and affordability of advanced diagnostic tools, such as genomic sequencing and molecular profiling. Countries like China and India are increasingly integrating next-generation sequencing (NGS) technologies into clinical practice, making genomic testing more accessible to a larger population. The ability to conduct detailed genomic and molecular profiling helps physicians better understand the unique characteristics of tumors and tailor immuno-oncology therapies to individual patients, making treatment more precise and effective. The Asia Pacific region is becoming a hotspot for strategic collaborations between local biotechnology companies, global pharmaceutical players, and academic institutions. These partnerships are driving the development of innovative precision immuno-oncology therapies, leveraging cutting-edge research in genomics, molecular biology, and immunology. Multinational pharmaceutical companies are actively expanding their footprint in the APAC region through joint ventures and partnerships with local firms, helping accelerate the commercialization of precision immuno-oncology treatments in key markets.
Some
of the major companies operating in the Global
Precision Immuno-Oncology Market include:
- Adaptimmune
Therapeutics Plc
- Agenus
Inc.
- Amgen
Inc
- AstraZeneca
plc
- Bristol
Myers Squibb Company
- Celgene
Corporation
- Eli
Lilly and Company
- F.
Hoffmann-La Roche Ltd.
- Gilead
Sciences, Inc
- GlaxoSmithKline
Plc
Download Free Sample Report
Customers can also request 10% free
customization on this report
“Certain areas, particularly in North
America, are projected to exert significant demand for precision immune
oncology. The growth in the competitive landscape and the presence of
well-established companies in the market, committed to enhance the overall
wellbeing of people each year, are expected to contribute to a remarkable
growth of the Global Precision Immuno-Oncology Market in the forecast period,"
said Mr. Karan Chechi, Research Director of TechSci Research, a
research-based Global management consulting firm.
"Precision Immuno-Oncology Market – Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Cancer type (Lung cancer, Breast cancer, Prostate cancer, Melanoma, Others), By Treatment type (Checkpoint Inhibitors, Car T cell Therapy, Cancer Vaccines, Others), By Biomarker (PD-L1, BRCA, KRAS, EGFR, Others), By End-user (Hospital & Clinics, Research Institutes, Others), by region, and Competition", 2020-2030F has
evaluated the future growth potential of Global Precision Immuno-Oncology Market
and provides statistics & information on market size, structure, and future
market growth. The report intends to provide innovative market intelligence and
help decision makers take sound investment decisions. Besides, the report also
identifies and analyzes the emerging trends along with essential drivers,
challenges, and opportunities in Global Precision Immuno-Oncology Market.
Contact
TechSci Research LLC
420 Lexington Avenue, Suite 300,
New York, United States- 10170
Tel: +1-332-258-6602
Email: sales@techsciresearch.com
Website: www.techsciresearch.com